Drugs / TTYP01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07252440 | Dec 2025 → Oct 2028 expected | Alzheimer disease | Shanghai Auzone Biological Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06757504 | Jan 2025 → Feb 2026 overdue | autism spectrum disorder | Shanghai Auzone Biological Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06648304 | Apr 2023 → Jun 2024 | ischemic stroke | Shanghai Auzone Biological Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTYP01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06648304 ↗ |
| Route | Oral | “Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.” NCT06757504 ↗ |